Nairobi, July 1 -- A total of 626,621 patients with high blood pressure and diabetes missed treatment in the 2024/2025 financial year due to insufficient funding, particularly for essential medications, according to performance data from the Non-Communicable Diseases (NCD) Prevention and Control programme.

Essential medicines used to manage these conditions include amlodipine, losartan, enalapril, hydrochlorothiazide and nifedipine for hypertension and metformin, insulin and glibenclamide for diabetes.

This marked one of the steepest treatment gaps recorded for these two chronic conditions in recent years. Of the patients affected, 514,167 were hypertensive patients. The unit had planned to treat 1,107,365 hypertensive patients during t...